According to our findings, the higher incidence of both the FLT3 and the NPM1 mutation in CN-AML patients underscores that both FLT3 and NPM1 can be used as candidate genetic markers for predicting the prognosis of CN-AML patients. Here, FLT3 is linked to acute myeloid leukemia.